The study comprised a total of 107 healthy individuals and 382 patients with stage I-IV colorectal cancer (n=365) or colorectal adenomas (n=17) (collectively referred to as “CRC patients”).
| Dataset ID | Sample type | Sequencing panel | Sequencing platform |
|---|---|---|---|
| A | Tumor DNA and normal DNA | Whole-exome sequencing | Illumina NovaSeq 6000 |
| B | Tumor DNA and normal DNA | Whole-genome sequencing | Illumina NovaSeq 6000 |
| C | Tumor DNA and normal DNA | Targeted sequencing | Illumina NovaSeq 6000 |
| D | cfDNA from CRC patients | Targeted sequencing | Illumina NovaSeq 6000 |
| E | cfDNA from healthy individuals | Targeted sequencing | Illumina NovaSeq 6000 |
| F | Normal DNA | Targeted sequencing | Illumina NovaSeq 6000 |
| G | cfDNA from CRC patients | Targeted sequencing | Illumina NovaSeq 6000 |
Frydendahl et al. Error-corrected deep targeted sequencing of circulating cell-free DNA from colorectal cancer patients for sensitive detection of circulating tumor DNA
External researchers (academic or commercial) interested in analysing the colorectal cancer datasets will need to contact the Data Access Committee via email to cla@clin.au.dk. The Data Access Committee is formed of Claus Lindbjerg Andersen, Mads Heilskov Rasmussen, and Ole Halfdan Larsen (Department of Clinical Medicine, Aarhus University). Due to Danish Law, for the authors to be allowed to share the data (pseudo-anonymized) it will require prior approval from The Danish National Committee on Health Research Ethics (or similar) for the specific new research goal. The author (based in Denmark) must submit the application for ethical approval, with the external researcher(s) as named collaborator(s). In addition to ethical approval, a Collaboration Agreement and a Data Processing Agreement is required, both of which must be approved by the legal office of the institution of the author (data owner) and the legal office of the institution of the external researcher (data processor).